GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Price-to-Owner-Earnings

Telix Pharmaceuticals (Telix Pharmaceuticals) Price-to-Owner-Earnings : 1,030.00 (As of May. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-05-13), Telix Pharmaceuticals's share price is $10.30. Telix Pharmaceuticals's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.01. It's Price-to-Owner-Earnings for today is 1,030.00.


The historical rank and industry rank for Telix Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

TLPPF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 454.76   Med: 572.38   Max: 759.32
Current: 744.85

During the past 9 years, the highest Price-to-Owner-Earnings of Telix Pharmaceuticals was 759.32. The lowest was 454.76. And the median was 572.38.


TLPPF's Price-to-Owner-Earnings is ranked worse than
96.43% of 168 companies
in the Biotechnology industry
Industry Median: 34.925 vs TLPPF: 744.85

As of today (2024-05-13), Telix Pharmaceuticals's share price is $10.30. Telix Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Therefore, Telix Pharmaceuticals's PE Ratio for today is 936.36.

As of today (2024-05-13), Telix Pharmaceuticals's share price is $10.30. Telix Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $0.01. Therefore, Telix Pharmaceuticals's PE Ratio without NRI for today is 936.36.

During the past 9 years, Telix Pharmaceuticals's highest PE Ratio without NRI was 968.13. The lowest was 530.56. And the median was 667.78.


Telix Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Telix Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Price-to-Owner-Earnings Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - - - 687.50

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 687.50

Competitive Comparison of Telix Pharmaceuticals's Price-to-Owner-Earnings

For the Biotechnology subindustry, Telix Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telix Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's Price-to-Owner-Earnings falls into.



Telix Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Telix Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=10.30/0.01
=1,030.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telix Pharmaceuticals  (OTCPK:TLPPF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Telix Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.